Glucobay M 25 Tablet is a combination oral antidiabetic medication containing Acarbose 25 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Acarbose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, thereby reducing postprandial hyperglycemia. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control. This dual mechanism addresses both fasting and postprandial blood glucose levels, making Glucobay M 25 effective in achieving optimal glycemic targets when diet and exercise alone are insufficient. The tablet is typically administered orally, with the dose tailored according to patient response and tolerance. Common side effects may include gastrointestinal disturbances such as flatulence, diarrhea, and abdominal discomfort, which often diminish with continued use. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose levels and renal function is recommended during therapy. Glucobay M 25 should be used as part of a comprehensive diabetes management plan, including lifestyle modifications, to reduce the risk of diabetes-related complications.